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ment regimens for chronic myeloid leukemia. If further research were funded, stud-
ies should examine a combination of natural history, treatment, and quality of life 
parameters, especially the effectiveness of first-line TKI treatment.
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Objectives: The first goal was to adapt an existing Austrian decision-analytic 
model for chronic myeloid leukemia (CML) treatment to the US-American health 
care context. Secondly, we updated the model with new data and further treat-
ment strategies to identify the most effective and most cost-effective strategy for 
the treatment of CML patients with different sequential tyrosine kinase inhibi-
tors (TKIs). MethOds: We evaluated 18 different treatment strategies within the 
US-American setting in terms of survival, quality-adjusted survival and costs. For 
model parameters, data from literature, a US-American expert survey, the Utah 
Cancer Registry, and economic data from a US-American database were used. 
Evaluated treatment strategies included imatinib, dasatinib, nilotinib, bosutinib, 
ponatinib, stem-cell transplantation and chemotherapy. The Markov state-tran-
sition model was analyzed as a cohort simulation over a lifelong time horizon, 
a third-party payer perspective was adopted and a discount rate of 3% was used. 
Additionally, several deterministic and probabilistic sensitivity analyses were con-
ducted. Results: Imatinib without second-line TKI resulted in an incremental 
cost-utility ratio (ICUR) of $148,700/QALY gained (incremental cost-effectiveness 
ratio (ICER) of $128,800/Lys) compared to baseline strategy ‘chemotherapy’. Imatinib 
with second-line nilotinib yielded an ICUR of $217,100/QALY gained (ICER $242,200/
LY) compared to imatinib without second-line TKI. Imatinib followed by second-
line bosutinib had an ICUR of $331,300/QALY gained (ICER $265,100/LY) compared 
to imatinib followed by second-line nilotinib. Imatinib with second-line dasatinib 
produced an ICUR of $343,200/QALY gained (ICER $279,600/LY) compared to imatinib 
with second-line bosutinib. All remaining strategies were excluded due to domi-
nance. ICURs and ICERs obtained from the probabilistic sensitivity analysis deviated 
up to 6.5% (2.5%) compared to base-case ICURs (ICERs). cOnclusiOns: Based on 
our analysis and current treatment guidelines, we recommend imatinib followed 
by second-line nilotinib as the most cost-effective treatment strategy. Our model 
results may support clinicians and patients in CML treatment decision making.
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Objectives: To assess the cost-effectiveness of using brentuximab vedotin (BV) in 
treating relapsed or refractory Hodgkin Lymphoma compared to standard chemo-
therapy and allogeneic stem cell transplant in the Swedish health care setting. 
Brentuximab vedotin is a novel antibody drug conjugate targeting CD-30 and is 
indicated for treating relapsed/refractory Hodgkin Lymphoma. MethOds: A Markov 
model with a lifetime horizon was constructed to compare BV to chemotherapy or 
allogeneic stemcell transplant (alloSCT). The analysis had a societal perspective 
and included lost productivity using a human capital approach. The model uses 
comparators relevant to Sweden and all epidemiological and cost parameters were 
based on Swedish sources. Both costs and effects were discounted at 3% according 
to Swedish guidelines. Clinical effectiveness for BV was based on pivotal clinical 
trial results and published data from the literature for the comparators relevant to 
the reimbursement authorities and to enable long term modelling. Outcomes were 
measured in QALYs. Uncertainty was addressed both through probabilistic sensi-
tivity analysis and one-way analyses of central variables. Results: Brentuximab 
vedotin dominated alloSCT (i. e a lower treatment cost and a better health outcome) 
and the ICER when compared to chemotherapy was SEK 419 000 (€ 47 000). One-way 
sensitivity analyses showed that the results were stable when central variables 
were varied. The probabilistic analysis also showed that brentuximab vedotin had 
a high probability of being the most cost-effective treatment at the accepted thresh-
old values for all scenarios. cOnclusiOns: The ICERs calculated were all below 
commonly accepted willingness to pay for a QALY in Sweden for both comparator 
scenarios. Brentuximab vedotin is a cost effective treatment option for relapsed/
refractory Hodgkin Lymphoma in the Swedish health care setting.
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Objectives: This study estimated the cost-utility of axitinib after sunitinib failure 
in adult patients with renal cell carcinoma. Total costs and quality adjusted life 
years accrued with axitinib was compared to everolimus, the only drug for second 
line treatment financed by the Portuguese National Health Service. MethOds: 
A 4-week cycle Markov model with three health states (progression free, post 
progression, and death) was adapted to the Portuguese setting. In the absence of 
head-to-head clinical trials and the unfeasibility of a standard indirect comparison, 
relative efficacy was based on a previous simulated treatment comparison. Axitinib 
trial data on quality of life (utility) was used for the progression free stage and 
Objectives: To identify the dominant scheme of mRCC second-line target treat-
ment (compare two alternatives – Axitinib and Everolimus). MethOds: Based on 
the Markov model, the cost-effectiveness analysis was realized. Overall survival, 
annual survival rate, time to progression of disease and direct cost of mRCC treat-
ment was evaluated. Costs analysis included: costs of two target therapy lines 
(Sunitinib as a first-line in combination with Axitinib or Everolimus treatment); cost 
of 3 and 4 grade side effects compensation; cost of diagnosis and inpatient care; cost 
of disease progression; cost of palliative and best supportive care. Results: During 
the pharmacoeconomic analysis of Axitinib use as a second-line therapy for mRCC, 
it was found that this target therapy regimen would significantly increase the time 
to progression and the overall survival which amounted to 22,75 months, with an 
annual survival rate of 68%, 38% and 17% of patients following the first, second and 
third year of treatment, respectively. Despite the high cost of this treatment regimen, 
reaching 51.327 EUR at the horizon of ten year study, the treatment regimen includ-
ing Axitinib will be characterized by the lowest values of the cost-effectiveness 
ratio, reflecting the costs incurred by the health care system for patient’s life sav-
ing, and incremental cost-effectiveness ratio, which was less than willingness to 
pay threshold in Russia. cOnclusiOns: It is shown, Axitinib use as second-line 
of target therapy in patients with mRCC is the most preferable treatment regimen 
then Everolimus from the pharmacoeconomic point of view.
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Objectives: Demonstrate through an economic evaluation of cost-effectiveness 
that using Hydralazine LP magnesium valproate (Transkrip ®) associated with 
first-line chemotherapy in the treatment of persistent or recurrent metastatic 
stage IVB cervical cancer, type not candidates for surgery or radiotherapy is more 
effective than the alternatives available in Mexican health institutions: cisplatin 
with topotecan (CT), cisplatin with paclitaxel (CP), cisplatin with vinorelbine (CV), 
carboplatin with paclitaxel (CaP), paclitaxel (P), cisplatin and cisplatin with gem-
citabine © (CG). MethOds: A cost-effectiveness analysis was developed, using 
a Markov model with a time horizon of 2 years divided into 24 monthly cycles, 
the measure of effectiveness was determined as the years gained free survival 
(PFS), being an advanced cancer is significant, only were measured direct medi-
cal costs, an analysis of incremental cost-effectiveness was performed. To test 
the robustness of the model a deterministic and probabilistic sensitivity analysis 
was performed. Results:  The cost per patient using therapy with hydralazine LP 
magnesium valproate (Transkrip ®) is $ 142,109.93, gaining 0.8846 years in 
Progression free survival this treatment was more effective but more expensive, 
paclitaxel had a cost of $ 26,988.64 with 0.3631 years in PFS, this therapy is less 
expensive but more effective than all comparators. The ICER of (Transkrip ®) was 
$ 220.757 pesos per year in PFS versus paclitaxel. cOnclusiOns: The economic 
results of treatment of patients with metastatic cervical cancer, through an epige-
netic therapy with hydralazine LP magnesium valproate (Transkrip ®) over a time 
horizon of two years showed that hydralazine LP magnesium valproate (Transkrip 
®) is a cost effective alternative respect to comparators showed a greater response 
in years of progression-free survival and ICER below of 2 GDP.
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Objectives: Value-of-Information analysis can help to guide decision about future 
research priorities: If and what further research is needed? Our aim was to guide 
decision regarding future outcomes research on parameters related to different 
regimens for chronic myeloid leukemia (CML). MethOds: We updated a previously 
developed state-transition Markov model of CML, which evaluates seven treatment 
regimens including tyrosine kinase inhibitors, chemotherapy and stem cell trans-
plantation (SCT). We derived model parameters from published trials data, Austrian 
clinical, epidemiological, and economic data. We performed a cohort simulation over 
a lifetime horizon, adopted a societal perspective, and discounted costs and benefits 
at 3% annually. We calculated the expected value of perfect information (EVPI), 
partial perfect information (EVPPI), and the population EVPI (PEVPI). Additionally, 
we examined the expected value of sample information (EVSI) for different trial 
sizes. Results: Three strategies are on the efficiency frontier: imatinibàchemo-
therapy/SCT, nilotinibàchemotherapy/SCT (140,000 € /QALY) and nilotinibàdasat-
inibàchemotherapy/SCT (176,000 € /QALY). The EVPI for eliminating all uncertainty 
resulted in a curve with two peaks. One peak is around a WTP threshold of 150,000 
€ /QALY (EVPI 4,600 € ) and another peak is at 180,000 € /QALY (EVPI 7,700 € ). The PEVPI 
for Austria assuming a 10-year technology horizon was 2.5 million € (WTP 150,000 
€ /QALY) and 4.5 million € (WTP 180,000 € /QALY). EVPPI identified four parameters 
most responsible for decision uncertainty: duration of first-line therapy, probability 
of progressing from chronic phase to accelerated phase, probability of receiving a 
SCT, and the health-utility after SCT. The EVSI commented on the optimal study 
size for these parameters given the cost of obtaining information. cOnclusiOns: 
Acquiring additional evidence could prove valuable for determining optimal treat-
